Breast Biopsies May Cause Recurrent Metastatic Breast Cancer (rMBC)

The Good News Book

Breast cancer is a scary disease…especially if you still don’t have a clue how to protect yourself. In 2012 an eminent Boston College biologist wrote a landmark text, describing how and why breast cancer (actually any type of cancer) develops in one person, but not in another. Using this life-saving knowledge, Busting Breast Cancer describes at least five effective life style steps every woman can take to protect ourselves from developing this logical metabolic disease called breast cancer.

The Bad News

Women who have been treated for early-stage breast cancer worry their breast cancer will come back. They worry their disease will come back as recurrent metastatic breast cancer or rMBC. Breast cancer clinicians know that 30 to 40 percent of women who are “successfully treated”…are not!!! Instead, tens of thousands of breast cancer “survivors” arrive back at oncologists’ doors each year, now facing that terminal stage/stage IV rMBC diagnosis. This recurrence can happen within months, years or decades of a woman’s initial biopsies, radiation, surgeries, chemotherapies and/or “after-treatment” drugs…also called adjuvant drugs. WHY is this happening?

The Danger of a Single Breast Biopsy

A growing number of oncologists, cancer surgeons, biologists, and epidemiologists understand that even a single breast biopsy can create or cause recurrent metastatic breast cancer. HOW? As described in Chapter 1 of Busting Breast Cancer, a breast biopsy can cause that nasty biological scenario, known in the cancer world as the Seed and Soil Theory of Metastasis.

Size Does Not Matter

A 2018 statistical study also shows us that the size of your initial or primary breast tumor has little to do with your risk of developing rMBC. This same study also illustrates that the involvement or lack of involvement of your lymph nodes when diagnosed with that initial or primary tumor, has little to do with your risk of developing rMBC. See Dr. Steven Narod’s “The relationship between tumor size, nodal status and distant metastases: on the origins of breast cancer.”

Dr. Narod’s startling statistical discoveries that “tumor size does not matter,” and that ‘lymph involvement does not matter,” help support many biologists’ and clinicians’ understanding that breast biopsies are truly the culprit in the initiation of many rMBC diagnoses.

Thankfully biopsies are now an unnecessary procedure when a woman uses metabolic therapies to manage her breast cancer diagnosis. Women must now call for clinical trials that compare non-toxic metabolic therapies with cancer center’s current genetics-based toxic therapies, beginning with breast biopsies.

Let’s try to find ways to lower the number of early-stage breast cancer “survivors” who go on to become rMBC patients. Women must demand clinical trials that avoid biopsies, along with today’s other toxic treatments if we want to find ways to successfully treat many more early- stage breast cancer patients.